a predictable increase in the proliferative rate of malignant cells remaining after initial cytoreduction in vivo forms the rationale for timed sequential therapy ( tst ) with 1-b-d-arabinofuranosylcytosine ( ara-c ) for adult acute myelogenous leukemia ( aml ) .
C0334227
malignant cells
C0220615
adult acute